PreludeDx

“My #DCIS was the size of a grain of rice.” Even though it was tiny, it changed Jennifer Douglas’s life — in a big way. As a #DCIS survivor, author and patient advocate, she looks back on her journey and shares why a lumpectomy was the right surgical choice for her.

The day before her 42nd birthday — Jennifer Douglas was diagnosed with #DCIS. In this video, Jennifer, a DCIS survivor, author and patient advocate, reads an excerpt from her book, “A Breast Cancer Journey: Living It One Step At a Time.” In this clip, she talks about what it felt like when she was told she had breast cancer.

We’d like to introduce you to Jennifer Douglas, Author, #DCIS survivor and patient advocate. During #BreastCancerAwareness month, we’ll share videos of her reading excerpts from her book, “A Breast Cancer Journey: Living It One Step At a Time.” Jennifer’s videos are for everyone — her first-hand account helps #breastcancer patients, family members and caregivers understand just what it’s like to go through the diagnosis, treatment and recovery of this disease, and the impact it has on all. Stay tuned.

Our latest study, published in Clinical Breast Cancer, marks a significant advancement for HER2-positive #DCIS patients. Our #DCISionRT test successfully identified two distinct groups of HER2(3+) DCIS patients treated with breast-conserving surgery (BCS) plus radiation therapy (RT). Patients with the newly identified Residual Risk subtype showed significantly higher in-breast recurrence rates (16.2% vs 1.6%, p=.01). And 63% of HER2(3+) patients had the Residual Risk subtype, suggesting an opportunity to refine treatment strategies for those patients. What does this mean? ·     More precise risk stratification for #DCIS patients. ·     Potential for tailored treatments, including the possible benefit of Trastuzumab. ·     Empowering physicians and patients to make more informed decisions about treatment plans. Read more: https://lnkd.in/g-mqqDkx

During #ASTRO24, our conversations have reinforced the essential role #DCISionRT plays in creating personalized #DCIS treatment plans. Two big takeaways: ·     Radiation oncologists are recognizing the value of #DCISionRT because it’s a predictive and prognostic test that’s proven to improve patient outcomes. ·     DCISionRT helps streamline the consultation process and empowers more informed decision-making.

Jennifer Douglas, a #DCIS survivor, patient advocate and author, shares her experience on how #DCISionRT offered her a window into her DCIS that she didn’t have before. Learn more about this test and how it’s empowering doctors and patients to change the way they evaluate radiation treatment options. https://bit.ly/3N8RNaP

#ASTRO24 attendees: Stop by our booth (right by the escalator) for coffee, candy and conversation. #DCISionRT #DCIS #PreludeDX

Come see us in booth 909 at the American Society for Radiation Oncology (ASTRO) conference next week in DC. PreludeDx highlights include: • Featured Poster: The PREDICT II Registry: A Prospective Study to Evaluate the Clinical Utility of a 7-Gene Predictive Biosignature on Treatment Decisions in Patients with DCIS (9/30, 3-4pm ET) • Featured Quick Pitch: A Novel Comprehensive Multi-Omic Biosignature to Assess Recurrence Risk and Adjuvant Therapy Benefit in Early-Stage Hormone-Positive Invasive Breast Cancer Patients (10/2, 8:20-8:30am ET) You can also meet the PreludeDx team at booth 909 and schedule a one-on-one meeting with our Scientific Leadership. See you soon at #ASTRO24!

The FDA issued a new rule requiring all mammography reports to include information about breast density. This is a significant step forward in women’s health, as breast density is both a risk factor for breast cancer and can make detection more challenging. Remarkably, about half of women over age 40 have dense breasts, as categorized on the BI-RADS scale (A-D), with A being least dense and D being the most dense. At PreludeDx, we understand the importance of comprehensive risk assessment in breast cancer prevention and early detection. For patients with #DCIS, our risk assessment test, #DCISionRT, predicts the benefit of radiation therapy after breast conserving surgery, and helps guide treatment decisions. For more information on the FDA’s ruling, read more: Read more: https://bit.ly/47vdQBI

Radiation therapy has become more personalized within the past decade. Dr. Ramji R. Rajendran from Alexian Brothers Cancer Institute reminds #DCIS patients that there is a test that can help physicians better tailor their treatment decisions. He encourages patients to ask for #DCISionRT to help guide treatment discussions as part of their standard of care: https://lnkd.in/eU4gRjV; Learn Look Locate